GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Medeon Biodesign Inc (ROCO:6499) » Definitions » Debt-to-Asset

Medeon Biodesign (ROCO:6499) Debt-to-Asset : 0.08 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Medeon Biodesign Debt-to-Asset?

Medeon Biodesign's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was NT$50.7 Mil. Medeon Biodesign's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was NT$152.8 Mil. Medeon Biodesign's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was NT$2,557.8 Mil. Medeon Biodesign's debt to asset for the quarter that ended in Mar. 2024 was 0.08.


Medeon Biodesign Debt-to-Asset Historical Data

The historical data trend for Medeon Biodesign's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medeon Biodesign Debt-to-Asset Chart

Medeon Biodesign Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.05 0.15 0.01 0.05

Medeon Biodesign Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Mar24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.06 0.07 0.07 0.08

Competitive Comparison of Medeon Biodesign's Debt-to-Asset

For the Medical Instruments & Supplies subindustry, Medeon Biodesign's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medeon Biodesign's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Medeon Biodesign's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Medeon Biodesign's Debt-to-Asset falls into.



Medeon Biodesign Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Medeon Biodesign's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(36.686 + 162.224) / 4040.023
=0.05

Medeon Biodesign's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(50.667 + 152.789) / 2557.756
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medeon Biodesign  (ROCO:6499) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Medeon Biodesign Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Medeon Biodesign's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Medeon Biodesign (ROCO:6499) Business Description

Traded in Other Exchanges
N/A
Address
No. 116, HouGang Street, 7th Floor, Shilin District, Taipei, TWN, 11170
Medeon Biodesign Inc develops medical device products. The main services of the Group are the research and development of medical devices, manufacturing, and sale of injection molding and components of medical devices. The company provides products in the fields of cardiovascular and laparoscopic. Its business includes Medical Device Development Department and Medical Device Components Manufacturing and Sales Department. The majority of the company revenue comes from Medical Device Components Manufacturing and Sales Department segment. The company revenue is mainly derived from the USA.

Medeon Biodesign (ROCO:6499) Headlines

No Headlines